Mozart K.448 acts as a potential add-on therapy in children with refractory epilepsy
Mozart K.448 acts as a potential add-on therapy in children with refractory epilepsy
复制标题
DOI：
10.1016/j.yebeh.2010.12.044
复制
发表时间：
2011-03-01
影响因子：
2.6
通讯作者：
Yang, Rei-Cheng
中科院分区：
文献类型：
--
作者：
Lin, Lung-Chang;Lee, Wei-Te;Yang, Rei-Cheng
莫扎特的D大调双钢琴奏鸣曲，K.448（莫扎特K.448），已被证明可以改善心理功能，导致所谓的莫扎特效应。我们以前的工作表明，癫痫儿童的癫痫样放电减少期间和听莫扎特K.448后立即。在这项研究中，我们评估了莫扎特1（448）对儿童难治性癫痫的长期影响。11名难治性癫痫儿童入组。所有患者均确诊为难治性癫痫1年以上（范围1年~ 6年4个月，平均3年11个月），并接受至少2种抗癫痫药物（AED）治疗。在研究期间，他们每天睡前听一次莫扎特K.448，持续6个月。在他们开始听这种音乐之前6个月和研究期间每月记录癫痫发作频率。在6个月的研究期间，所有患者均使用相同的AED。癫痫发作的频率进行了比较之前和之后听莫扎特K.448。11例患者中有8例在听莫扎特K.448 6个月后无癫痫发作（N = 2）或反应非常好（N= 6）。其余三种（27.3%）显示出最小或没有效果（有效性< 50%;癫痫发作频率未改变或恶化）。癫痫发作平均减少53.6 +/-62.0%。智商病因或性别在癫痫发作减少方面没有显著差异。我们的结论是，莫扎特K.448应进一步研究作为一个潜在的添加治疗儿童难治性癫痫。(C)2011 Elsevier Inc. All rights reserved.
Mozart's Sonata for two pianos in D major, K.448 (Mozart K.448), has been shown to improve mental function, leading to what is known as the Mozart effect. Our previous work revealed that epileptiform discharges in children with epilepsy decreased during and immediately after listening to Mozart K.448. In this study, we evaluated the long-term effects of Mozart 1(448 on children with refractory epilepsy. Eleven children with refractory epilepsy were enrolled. All of the patients were diagnosed as having had refractory epilepsy for more than 1 year (range = 1 year to 6 years 4 months, mean = 3 years 11 months) and had been receiving at least two antiepileptic drugs (AED). During the study period, they listened to Mozart K.448 once a day before bedtime for 6 months. Seizure frequencies were recorded 6 months before they started listening to this music and monthly during the study period. All of the patients remained on the same AEDs during the 6-month study period. Frequencies of seizures were compared before and after listening to Mozart K.448. Eight of eleven patients were seizure free (N = 2) or had very good responses (N= 6) after 6 months of listening to Mozart K.448. The remaining three (27.3%) showed minimal or no effect (effectiveness < 50%; unmodified or worsened seizure frequency). The average seizure reduction was 53.6 +/- 62.0%. There were no significant differences in seizure reduction with IQ etiology, or gender. We conclude that Mozart K.448 should be further studied as a potential add-on therapy in the treatment of children with refractory epilepsy. (C) 2011 Elsevier Inc. All rights reserved.